Intratracheal albuterol: a potential intervention for the asthma toolbox.

In this issue of RESPIRATORY CARE, Johnston et al1 remind us of a route of medication delivery that is often overlooked: intratracheal. The stimulus for the project was the death of children with a severe asthma attacks who had received numerous doses of albuterol by metered-dose inhaler (MDI), yet had no relief. The purpose of this study was to compare the effectiveness of liquid bolus administration of a bronchodilator (2.5 mg of albuterol in 1.25 mL of normal saline in 2 doses while positioned laterally) versus the MDI (360 g) in the treatment of acute bronchospasm in mechanically ventilated subjects. The authors reviewed the literature on the administration of albuterol in intubated and mechanically ventilated subjects and the physics of fluid flow in obstructed airways in surfactant administration to explain the potential effectiveness of albuterol administered via an endotracheal tube. They demonstrated that albuterol may be instilled into an endotracheal tube in mechanically ventilated subjects with airway obstruction, yielding results similar to those obtained when using an MDI. A MEDLINE search of literature since 1996 reveals very few references to intratracheal instillation of medications. Intratracheal instillation has been used in the treatment of arrhythmias and respiratory depression, as lidocaine, epinephrine, atropine, and naloxone are administered by this route during resuscitation when intravenous access is not available.2 Unfortunately, in a retrospective study3 of resuscitation success, medications given at recommended doses (twice the intravenous dose followed by a flush) for injection into an endotracheal tube during cardiac arrest and cardiopulmonary resuscitation (CPR) were of no benefit. This may be because of the poor perfusion during CPR such that the drugs never made it to the circulation or